Try GOLD - Free
'Pvt investment to pick up from second half of FY24'
Business Standard
|December 07, 2023
India's growth prospects have brightened and, with capacity utilisation touching 70-90 per cent in three straight quarters, private investment is set to bounce back, says Confederation of Indian Industry (CII) President R DINESH. In an interview with Asit Ranjan Mishra & Shiva Rajora in New Delhi, Dinesh proposes a green transition fund to manage the climate challenge. Edited excerpts:
What are India's medium-term growth prospects? How do you see headwinds and tailwinds playing out?
At the start of my term (as CII president), I had predicted that India will grow at a rate between 6.5 per cent and 6.7 per cent. Now, after the first half, I am confident to raise the rate to 6.8 per cent. For next year, the growth rate could be 7 per cent, though it will become clearer in the latter part of the year.
The headwinds mostly are macroeconomic and global issues.
Volatility is the larger challenge-things that unfold within a week or two. Those are the kind of big challenges we have. The good news is that the negative situation has bottomed out in Europe at least. The US is doing well, and we hope it will continue to do so.
As for tailwinds, some good work has been done on the infrastructure front. The ease of doing business has shifted to the cost of doing business, and the latter has two important pillarsinfrastructure investment and digitisation. Also, amid global volatility, India has become a sweet spot. Its large domestic market gives it the scope of becoming an export hub, so there is significant interest among foreign investors. In a way, that interest has continued after Covid.
If India's growth prospects, as you highlight, are bright, why has India Inc become risk-averse? With private investment not growing, we seem to be relying solely on the government's capital expenditure.
This story is from the December 07, 2023 edition of Business Standard.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Business Standard
Business Standard
Labour Codes impact: HCL tech profit slips 11%
Q3 top line beats Street estimates, bottom line misses expectations
2 mins
January 13, 2026
Business Standard
New labour Codes, restructuring weigh on TCS earnings
Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.
1 min
January 13, 2026
Business Standard
Black drives the thrill for car buyers
Sees a surge in yearly sales, while white remains practical 'utility king'
2 mins
January 13, 2026
Business Standard
CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS
Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be
2 mins
January 13, 2026
Business Standard
China’s PVC rethink to help India pipe makers
Supply likely to tighten after S-PVC rebate withdrawal
2 mins
January 13, 2026
Business Standard
Responsible growth
India must ensure data centres are sustainable
2 mins
January 13, 2026
Business Standard
India’s GenZ is full of creativity: PM
Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.
1 min
January 13, 2026
Business Standard
Iran wants to negotiate after threats to attack, says Trump
At least 572 killed in protests; Tehran says situation ‘under full control’
2 mins
January 13, 2026
Business Standard
Insurers knock on Irdai door for clarity on director overlap ban
CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY
2 mins
January 13, 2026
Business Standard
Delhi HC allows Zydus to sell generic version of cancer drug
Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.
1 min
January 13, 2026
Translate
Change font size
